Pharma Update

Astegolimab: Potential for biologic addressing broadest population Aiming to address all COPD patients COPD patient population overview¹ Roche Low 80% High 20% EOS* مر | Smoking Astegolimab target patient population: Low EOS High Former Current Former 70% Current 30% Smoking • Near-term biologics in COPD are focused on EOS high or former smokers only · Astegolimab with a unique potential to cover EOS low to high, as well as former and current smokers 1 Global strategy for prevention, diagnosis and management of COPD: 2023 report; *EOS high defined as ≥300 eosinophil cells per microliter of blood and EOS low defined as <300 eosinophil cells per microliter of blood; COPD-chronic obstructive pulmonary disease; SoC-standard of care; SC=subcutaneous; Q4W-every 4 weeks; EOS-eosinophils 113

View entire presentation